MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.8% – Here’s What Happened

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) rose 0.8% on Tuesday. The company traded as high as $1.21 and last traded at $1.19. 227,056 shares were traded during trading, a decline of 68% from the average daily volume of 706,538 shares. The stock had previously closed at $1.18.

MAIA Biotechnology Trading Down 2.5%

The stock has a fifty day moving average of $1.32 and a two-hundred day moving average of $1.34. The company has a market capitalization of $71.00 million, a PE ratio of -1.85 and a beta of 0.27.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its earnings results on Monday, August 10th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities analysts forecast that MAIA Biotechnology, Inc. will post -0.54 EPS for the current year.

Insider Activity

In other MAIA Biotechnology news, Director Ramiro Guerrero acquired 37,595 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were purchased at an average cost of $1.32 per share, for a total transaction of $49,625.40. Following the transaction, the director owned 773,296 shares in the company, valued at $1,020,750.72. This represents a 5.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vlad Vitoc bought 73,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were acquired at an average price of $1.37 per share, with a total value of $100,010.00. Following the acquisition, the chief executive officer owned 1,049,121 shares of the company’s stock, valued at $1,437,295.77. This represents a 7.48% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 258,078 shares of company stock worth $352,426 over the last three months. 19.81% of the stock is owned by insiders.

Institutional Trading of MAIA Biotechnology

Hedge funds and other institutional investors have recently modified their holdings of the business. Susquehanna International Group LLP bought a new stake in MAIA Biotechnology during the second quarter worth about $51,000. Cable Car Capital LP purchased a new stake in MAIA Biotechnology during the 2nd quarter valued at about $741,000. BlackRock Inc. purchased a new position in MAIA Biotechnology in the second quarter worth about $580,000. Centric Wealth Management purchased a new stake in shares of MAIA Biotechnology during the second quarter valued at approximately $1,107,000. Finally, PVG Asset Management Corp bought a new stake in shares of MAIA Biotechnology during the first quarter valued at approximately $46,000. 5.65% of the stock is owned by hedge funds and other institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company’s research is centered on telomere biology, an area that seeks to exploit the mechanisms cancer cells use to maintain their ability to divide and survive.

MAIA’s lead investigational product is atebimetostat, also known as THIO or 6-thio-2′-deoxyguanosine. The small-molecule therapy is designed to induce telomere dysfunction and promote the death of cancer cells.